Business · 22/11/20261 min read
CARsgen Presents First Clinical Data on Its In Vivo CAR-T Product Candidate CT1182
Summary
SHANGHAI, Nov. 22, 2026 — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces the clinical data from CT1182 (KJ-C2529), a CD19/CD20-targeting in vivo CAR T-cell product candidate developed on...